The largest database of trusted experimental protocols

6495b mass spectrometer

Manufactured by Agilent Technologies

The Agilent 6495B is a high-performance triple quadrupole mass spectrometer designed for analytical applications. It features advanced ion optics and a high-efficiency ion source to provide enhanced sensitivity and resolution for quantitative and qualitative analysis.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using 6495b mass spectrometer

1

Quantitative LC-MS/MS Assay for Plasma Peptides

Check if the same lab product or an alternative is used in the 5 most similar protocols
The SIS peptide mixture was solubilized in 220 μl of 30% ACN/0.1% FA, transferred to a 15-mL Falcon tube, and then diluted to 10× LLOQ per μL with 0.1% FA. A 45-μL aliquot of plasma digest was transferred into a well of an Eppendorf LoBind skirted PCR plate and spiked with 45 μl of the SIS peptide mixture. For each standard curve point and each QC sample, 55 μl of BSA surrogate matrix digest (143 μg/ml) was spiked with 55 μl of the SIS peptide mixture, as well as 55 μl of a level-specific light peptide mixture at a ratio of 1:1:1 (v/v/v). Plasma samples were then concentrated by solid-phase extraction (SPE) using an Oasis HLB μElution plate. Briefly, the SPE plate was conditioned with 600 μl of MeOH, equilibrated with 600 μl of 0.1% aqueous FA, followed by sample loading. The wells were washed three times with 600 μl of H2O, and the bound peptides were eluted with 55 μl of 70% ACN/0.1% FA. After the SPE step, the eluates were evaporated using a speed vacuum concentrator and were then stored at −80 °C. Plasma samples, standards, and QC samples were then resolubilized and analyzed on an Agilent 6495B mass spectrometer.
+ Open protocol
+ Expand
2

Peptide Transitions and LCMS Transferability

Check if the same lab product or an alternative is used in the 5 most similar protocols
To assess whether peptide transitions and the LCMS method were transferable between laboratories a set of processed samples using the original immunodepletion method were split and run at two sites (Sciex 4000 QTRAP at the development laboratory and a Sciex 5500 QTRAP at Sydney Mass Spectrometry, University of Sydney).
To establish the clinical robustness of the immunoaffinity method 100 plasma samples were independently processed and analysed in the development laboratory and a third site (Atturos (Dublin, Ireland)). This comparison laboratory used an Agilent 1290 LC and 6495B mass spectrometer for detection. For comparison between laboratories biomarker concentrations were adjusted using the respective mean bias determined from Bland Altman Plot analysis, as described above. To be able to compare the risk predictions the comparison laboratory data was further adjusted to the immunodepletion concentrations as had already being done for the development laboratory values.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!